Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, will present a deep learning study on Epidermal Growth Factor Receptor (EGFR) mutation prediction in patients with non-small cell lung cancer (NSCLC) at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2025, held from April 25 to 30 in Chicago, Illinois.

Lunit，一家为癌症诊断和治疗提供人工智能解决方案的领先提供商，将在即将到来的2025年美国癌症研究协会（AACR）年会上展示一项关于非小细胞肺癌（NSCLC）患者表皮生长因子受体（EGFR）突变预测的深度学习研究。该会议将于4月25日至30日在伊利诺伊州芝加哥举行。

The study, which highlights the development and validation of the Lunit SCOPE Genotype Predictor, an AI-powered deep learning model capable of predicting EGFR mutations directly from hematoxylin and eosin (H&E)-stained tissue samples in NSCLC patients, will be presented in collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN)..

这项研究重点介绍了Lunit SCOPE基因型预测器的开发和验证，这是一种由人工智能驱动的深度学习模型，能够直接从非小细胞肺癌患者的苏木精和伊红（H&E）染色组织样本中预测EGFR突变，该研究将与阿斯利康（LSE/STO/Nasdaq：AZN）合作发表。

EGFR mutation testing plays a crucial role in determining the best course of treatment for patients with NSCLC, yet many patients remain untested due to logistical and resource constraints, despite guideline recommendations. Existing AI models designed to predict mutations from pathology images have faced limitations in real-world clinical applications due to limited training data and lack of validation.

EGFR突变检测在确定非小细胞肺癌（NSCLC）患者的最佳治疗方案中起着至关重要的作用，但由于后勤和资源限制，许多患者仍未接受检测，尽管指南有相关推荐。现有的用于从病理图像预测突变的人工智能模型，因训练数据有限且缺乏验证，在现实临床应用中面临局限性。

Lunit and AstraZeneca's collaborative study leveraged the largest and most diverse training dataset to date, consisting of more than 12,000 pathology slides (>4,500 EGFR-mutated and >7,500 wild-type) from NSCLC patients across multiple countries, including the US, China, and South Korea, to further develop and validate Lunit's model..

Lunit与阿斯利康的合作研究利用了迄今为止规模最大、多样性最丰富的训练数据集，包含来自美国、中国、韩国等多个国家的非小细胞肺癌患者的12,000多张病理切片（超过4,500张EGFR突变型和7,500张野生型），以进一步开发和验证Lunit的模型。

The AI model's performance remained consistent across key clinical variables including specimen types, EGFR mutation subtypes, slide scanners, and scan magnifications, reinforcing its potential for real-world deployment in diverse clinical environments.

该人工智能模型在包括样本类型、EGFR突变亚型、玻片扫描仪和扫描放大倍数等关键临床变量上表现一致，进一步证明了其在多样化临床环境中实际部署的潜力。

The collaboration focuses on the development of the Lunit SCOPE Genotype Predictor, an AI-driven tool designed to rapidly and cost-effectively predict NSCLC driver mutations from H&E-stained tissue samples.

该合作专注于开发Lunit SCOPE基因型预测器，这是一款人工智能驱动的工具，旨在快速且经济高效地从H&E染色的组织样本中预测非小细胞肺癌驱动突变。

'This study is a testament to the real-world potential of AI in precision oncology,' said Brandon Suh, CEO of Lunit. 'By leveraging Lunit AI, we have demonstrated that routine pathology slides can serve as a powerful tool to predict EGFR mutations with high accuracy. This could help clinicians prioritize molecular testing for NSCLC patients, ensuring that patients receive targeted therapy without unnecessary delays.

“这项研究证明了人工智能在精准肿瘤学中的现实潜力，”Lunit首席执行官Brandon Suh表示。“通过利用Lunit AI，我们已经证明常规病理切片可以作为一种强大的工具，以高准确度预测EGFR突变。这可以帮助临床医生优先为NSCLC患者进行分子检测，确保患者及时接受靶向治疗，避免不必要的延误。”

We are excited to showcase this breakthrough at AACR 2025, reinforcing our commitment to advancing AI-driven precision oncology in collaboration with AstraZeneca.'.

我们很高兴在2025年AACR展示这一突破性成果，这进一步巩固了我们与阿斯利康合作推动人工智能驱动的精准肿瘤学发展的承诺。

Join Us at AACR 2025

参加2025年AACR会议

Visit Lunit at AACR 2025 Booth #2843 to learn more about this study and how AI is advancing precision oncology and improving patient outcomes.

访问2025年AACR会议Lunit展位#2843，了解更多关于这项研究的信息，以及人工智能如何推动精准肿瘤学的发展并改善患者预后。

About Lunit

关于Lunit

Founded in 2013, Lunit (KRX:328130.KQ) is a medical AI company on a mission to conquer cancer through AI. Lunit harnesses AI-powered medical image analytics and biomarker analysis to ensure accurate diagnosis and optimal treatment for each cancer patient. The FDA-cleared Lunit INSIGHT suite for cancer screening serves over 4,800 medical institutions across 55+ countries.

Lunit（KRX:328130.KQ）成立于2013年，是一家致力于通过人工智能战胜癌症的医疗AI公司。Lunit利用人工智能驱动的医学影像分析和生物标志物分析，为每位癌症患者提供精确诊断和最佳治疗方案。获得FDA批准的Lunit INSIGHT癌症筛查套件已服务于55多个国家的4800多家医疗机构。

Lunit clinical studies have been published in top journals, including the Journal of Clinical Oncology and the Lancet Digital Health, and presented at global conferences such as the ASCO and RSNA. Headquartered in Seoul, South Korea, with a network of offices worldwide, Lunit leads the global fight against cancer.

Lunit的临床研究已发表在顶级期刊上，包括《临床肿瘤学杂志》和《柳叶刀数字健康》，并在全球会议如ASCO和RSNA上展示。Lunit总部位于韩国首尔，在全球设有办事处网络，领导着全球抗癌斗争。

Discover more at lunit.io..

访问 lunit.io 发现更多。

Source: prnewswire.com

来源：prnewswire.com